

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Hans Lennernas	10/02/1998
RECEIVING PARTY DATA	
Name:	Diabact AB
Street Address:	Box 303
City:	05 UPPSALA
State/Country:	SWEDEN
Postal Code:	SE-751
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7910132
CORRESPONDENCE DATA	
Fax Number:	2027786493
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2026626493
Email:	ismith@cov.com
Correspondent Name:	Isatta B. Smith
Address Line 1:	1201 Pennsylvania Avenue, NW
Address Line 2:	1066
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20004-2401
ATTORNEY DOCKET NUMBER:	034065.0006-US02
NAME OF SUBMITTER:	Isatta B. Smith
Signature:	/Isatta B. Smith/
Date:	09/27/2013
Total Attachments: 14	

CH \$40.00 7910132

source=034065.0006-US02_HL#page1.tif
source=034065.0006-US02_HL#page2.tif
source=034065.0006-US02_HL#page3.tif
source=034065.0006-US02_HL#page4.tif
source=034065.0006-US02_HL#page5.tif
source=034065.0006-US02_HL#page6.tif
source=034065.0006-US02_HL#page7.tif
source=034065.0006-US02_HL#page8.tif
source=034065.0006-US02_HL#page9.tif
source=034065.0006-US02_HL#page10.tif
source=034065.0006-US02_HL#page11.tif
source=034065.0006-US02_HL#page12.tif
source=034065.0006-US02_HL#page13.tif
source=034065.0006-US02_HL#page14.tif

Mellan å ena sidan Diabact AB (nedan kallat "Diabact") Box 303, 751 05 UPPSALA, och å andra sidan Hans Lennernäs, nedan gemensamt kallade "Parterna", har denna dag ingåtts följande

AVTAL

1. Bakgrund och Definitioner

[REDACTED]

Med "Uppfinningen" avses en sublingual läkemedelsform innehållande fentanyl, eller annan substans i fentanylserien, avsedd för behandling av akut eller kronisk smärta.

Med "Produkten" avses en sublingual tablett, baserad på Uppfinningen, med farmaceutisk och klinisk dokumentation organiserad i form av en registreringsansökan enligt europeisk standard.

Med "Projektet" avses det arbete som krävs för att åstadkomma Produkten.

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Handwritten signature/initials.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

44
42

4. Rättigheter

Diabact skall äga samtliga rättigheter till Projektet, inkluderande samtliga rättigheter till Produkten och Uppfinningen (och de rättigheter som följer med ett eventuellt patent) samt all dokumentation (inkluderade kliniskt dokumentation) rörande Produkten.

Hans Lennernäs överlåter härmed samtliga sina rättigheter till Uppfinningen till Diabact.

Hans Lennernäs intygar att hela hans rätt till Uppfinningen överlåts till Diabact så att Diabact i eget namn kan söka och erhålla skydd för Uppfinningen i Sverige och utlandet.



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Handwritten signature]

HSL-
[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]


[Redacted text block]

Detta avtal har upprättats i två originalexemplar, varav parterna tagit var sitt.

Uppsala den 2 / 10 1998

DIABACT AB


Thomas Lundqvist


Hans Lennertz

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]


[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]



[REDACTED]



PATENT

REEL: 031307 FRAME: 0585

The following

AGREEMENT

has this day been entered into between Diabact AB (hereinafter called "Diabact") Box 303, 751 05 UPPSALA of the one part, and Hans Lennernäs, of the other part, hereinafter together called the "Parties"

1. Background and Definitions

The "Invention" means a sublingual form of drug containing fentanyl, or other substance in the fentanyl series, intended for treatment of acute or chronic pain.

The "Product" means a sublingual tablet, based on the Invention, with pharmaceutical and clinical documentation organised in the form of a registration application to European standard.

The "Project" means the work which is required to produce the Product.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

4. Rights

Diabact shall own all rights to the Project, including all rights to the Product and the Invention (and such rights as accompany any patent) as well as all documentation (including clinical documentation) concerning the Product.

Hans Lennernäs does hereby assign all of his rights to the Invention to Diabact.

Hans Lennernäs does certify that all of his rights to the Invention are assigned to Diabact so that Diabact is able to apply for and obtain protection for the Invention in its own name in Sweden and abroad.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

✓ 
This Agreement has been engrossed in two original parts, of which the Parties have taken one each.

Uppsala, 2.10.1998

DIABACT AB

[Signature]

Thomas Lundqvist

[Signature]

Hans Lennernäs

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]